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V arious treatment options are available for stage III locally advanced non-small cell lung cancer 
(NSCLC),  depending on the extent of the tumor.  
Surgery is recommended for resectable NSCLC,  and 
preoperative concurrent chemoradiotherapy (CCRT) is 
often selected when preoperative treatment is consid-
ered necessary.  Toyooka et al.  compared clinical out-
comes in patients who underwent preoperative CCRT 
and preoperative chemotherapy for locally advanced 
NSCLC and demonstrated that the former treatment 
group had a better prognosis [1].  In phase III trial 
INT0139,  an exploratory analysis showed improved 
overall survival (OS) in patients who underwent preop-
erative CCRT plus lobectomy compared with that in a 
matched cohort who received definitive CCRT [2].  
Definitive CCRT with platinum/taxanes is a standard 
first-line treatment option for unresectable stage III 
lung cancer [3 , 4].  In the era of radiotherapy alone and 
CCRT,  the total dose of definitive radiotherapy is 
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Palliative concurrent chemoradiotherapy (CCRT) is often administered to patients with stage III non-small cell 
lung cancer (NSCLC).  We investigated the clinical outcomes of patients receiving palliative CCRT for NSCLC.  
Data of patients with NSCLC who underwent palliative CCRT (n = 16),  preoperative CCRT plus surgery 
(n = 97),  or definitive CCRT (n = 48) were evaluated.  In all groups,  the concurrent chemotherapy regimens 
consisted of cisplatin and docetaxel.  Rates of local control (LC),  distant metastasis-free survival (DMFS),  pro-
gression-free survival (PFS),  overall survival (OS),  and prognosis were compared.  The 2-year rates of LC,  
DMFS,  PFS,  and OS in 16 patients who underwent palliative CCRT were 44.4%,  12.5%,  12.5%,  and 18.8%,  
respectively.  Univariate analysis showed that palliative CCRT was associated with poor LC (p< 0.001),  DMFS 
(p< 0.001),  PFS (p< 0.001),  and OS (p< 0.001) outcomes in patients who completed CCRT as a preoperative 
treatment and poor LC (p= 0.01),  DMFS (p= 0.003),  PFS (p= 0.04),  and OS (p= 0.004) outcomes in patients who 
were considered for definitive CCRT.  Although there were some long-term survivors,  the clinical outcomes of 
palliative CCRT were significantly inferior to those of the ideal treatments.  Therefore,  careful determination of 
the appropriate treatment indications and further studies are warranted.
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defined as 54-66 Gy [5-7].  In some cases,  palliative 
CCRT is administered when ideal treatments are not 
adopted for various reasons.  Some patients do not 
undergo surgery despite completing CCRT as a preop-
erative treatment [2 , 8] or do not receive a definitive 
dose because of a dose constraint of the spinal cord or 
lungs [9 , 10].  Palliative CCRT for stage III NSCLC is 
presented as an option in the American Society for 
Radiation Oncology (ASTRO) guidelines [11].
Cisplatin/docetaxel is a standard regimen in Japan 
for concurrent administration with definitive radiother-
apy.  A cisplatin/docetaxel therapy group had better 
2-year survival rates than a second-generation chemo-
therapy group [3].  To the best of our knowledge,  there 
are no studies on palliative CCRT with cisplatin/docetaxel 
for stage III NSCLC.
The present study aimed to investigate the clinical 
outcomes of palliative CCRT with cisplatin/docetaxel as 
an initial treatment in comparison with the ideal treat-
ments in patients with stage III NSCLC.
Methods
Patients. We retrospectively reviewed the medi-
cal records of patients with stage III NSCLC who 
underwent palliative CCRT as an initial treatment with 
< 50 Gy between April 2003 and March 2018 at our 
institution.  Specifically,  we reviewed patients who did 
not undergo surgery despite having completed CCRT as 
a preoperative treatment and patients who had not been 
administered a definitive dose although they had been 
considered for definitive CCRT.  Patients treated with 
cisplatin/docetaxel as concurrent chemotherapy were 
included and those treated before CCRT were excluded.  
To compare palliative CCRT,  patients who underwent 
preoperative CCRT plus planned surgery were evalu-
ated,  as were those who underwent definitive CCRT 
within the same period.  Staging was performed using 
the UICC-TNM ver. 7.  This study was approved by the 
Institutional Review Board of Okayama University 
Hospital (approval number: 1809-018).  Patients were 
provided with the opportunity to opt out of the study at 
the outpatient ward or at the website.  This study con-
formed to the Declaration of Helsinki.
Treatment. All patients underwent three-dimen-
sional conformal radiotherapy.  The total dose for palli-
ative CCRT was defined as 40-50 Gy,  and that for 
definitive CCRT was defined as > 54 Gy; no planned 
surgery was performed before recurrence.  The total 
dose of preoperative CCRT was 40-60 Gy,  and planned 
surgery was performed after CCRT.  The details of the 
radiotherapy are described in previous studies [12 , 13].  
In all groups,  the concurrent chemotherapy regimens 
consisted of cisplatin 40 mg/m2 and docetaxel 40 mg/m2 
[3].
Statistical analyses. The rates of local control 
(LC),  distant metastasis-free survival (DMFS),  pro-
gression-free survival (PFS),  and OS after completion 
of CCRT were calculated.  We compared the clinical 
outcomes of the three categories of patients.  We further 
examined whether palliative CCRT was associated with 
prognosis.  The Kaplan−Meier method was used to 
determine survival rates,  the log-rank test was used for 
univariate analysis,  and the Cox proportional hazards 
test was used for multivariate analysis.  A p-value of 
<0.05 (two-sided) was considered statistically significant.  
R software (version 3.5.1,  R Foundation for Statistical 
Computing) was used for all statistical analyses.
Results
Of the 16 patients who underwent palliative CCRT,  
9 completed CCRT as a preoperative treatment and 7 
were considered for definitive CCRT.  Of the 9 who did 
not undergo surgery despite completing CCRT as a pre-
operative treatment,  7 had distant metastasis,  1 had 
deterioration of their general condition,  and 1 had 
deterioration of their general condition because of radi-
ation pneumonitis.  Moreover,  7 patients were not 
administered a definitive dose even though they were 
considered for definitive CCRT.  Of these,  3 patients 
had a lung dose constraint,  3 had a spinal cord dose 
constraint,  and 1 had both constraints.  Table 1 shows 
the characteristics of all 16 patients who underwent 
palliative CCRT.  The 2-year rates of LC,  DMFS,  PFS,  
and OS were 44.4%,  12.5%,  12.5%,  and 18.8%,  
respectively (Fig. 1).  Twelve patients died of lung can-
cer,  1 died of another disease,  2 were alive without 
recurrence,  and 1 was alive with recurrence.  The fol-
low-up periods for the 2 patients who were alive with-
out recurrence were 42.5 months and 87.5 months,  
respectively.
Ninety-seven patients underwent CCRT as a preop-
erative treatment plus planned surgery.  Table 2 shows 
the characteristics of 106 patients,  including these 97 
patients and the remaining 9 patients (8.5%) who did 
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not undergo surgery despite having completed CCRT as 
a preoperative treatment.  Kaplan−Meier curves for the 
group with preoperative CCRT plus surgery and pallia-
tive CCRT are shown in Fig. 2.  The 2-year rates of LC,  
DMFS,  PFS,  and OS were 95.7%,  68.9%,  65.8%,  and 
89.6%,  respectively,  for patients with preoperative 
CCRT plus surgery and were 60.0%,  11.1%,  11.1%,  
and 22.2%,  respectively,  in patients receiving palliative 
CCRT.  The 5-year rates of LC,  DMFS,  PFS,  and OS 
were 92.3%,  56.9%,  53.5%,  and 73.1%,  respectively,  in 
patients receiving preoperative CCRT plus surgery and 
60.0% and 22.2%,  respectively,  for LC and OS in 
patients receiving palliative CCRT (rates for DMFS and 
PFS were not available).  In the univariate analyses of 
the 106 patients,  palliative CCRT was associated with a 
low rate of LC (p < 0.001),  and palliative CCRT was 
associated with low rates of DMFS (p < 0.001),  PFS 
(p < 0.001),  and OS (p < 0.001).  In the multivariate anal-
yses,  palliative CCRT (p < 0.001),  T1-2 stage (p = 0.002),  
and location of the lower lobe (p = 0.009) were associated 
with a low rate of DMFS.  Palliative CCRT (p < 0.001),  
T1-2 stage (p < 0.001),  and location of the lower lobe 
(p = 0.01) were associated with a low rate of PFS.  
Palliative CCRT (p < 0.001) and the location of the lower 
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Table 1　 Characteristics of all patients who received palliative CCRT (n=16)
%
Age (years) Median (range) 64 (42-72) -
Sex Male 14 87
Female 2 13








Clinical stage IIIA 8 50
IIIB 8 50
Histology Adenocarcinoma 4 25
Squamous cell carcinoma 8 19
Adenosquamous carcinoma 1 6
Non-small cell carcinoma 3 50
Lobe Upper 10 62
Lower 6 38
Laterality Right 13 81
Left 3 19
Smoking history† Never 1 6
Former 5 31
Current 9 56
FEV1 (l)† Median (range) 2.22 (1.74-3.67) -
ECOG-PS 0 6 38
1 10 62
Radiation dose (Gy) Median (range) 46 (40-46) -
X-ray energy (MV) 6 1 6
10 15 94
Cycles of concurrent chemotherapy 1 6 38
2 10 62
Cycles of adjuvant chemotherapy 0 14 87
1-5 2 13
CCRT,  concurrent chemoradiotherapy; ECOG-PS,  Eastern Cooperative Oncology Group performance status; FEV1,  forced expiratory 
volume in 1 sec.
†These factors have missing values.
lobe (p = 0.018) were associated with low rates of OS.
Furthermore,  48 patients underwent definitive CCRT.  
Table 3 shows the characteristics of 55 patients,  includ-
ing these 48 patients and 7 others who were not admin-
istered a definitive dose although they were considered 
for definitive CCRT.  Kaplan−Meier curves for the 
groups with definitive CCRT and palliative CCRT are 
shown in Fig. 3.  The 2-year rates of LC,  PFS,  and OS 
were 64.3%,  39.2%,  37.2%,  and 59.7%,  respectively,  in 
patients receiving definitive CCRT and 20.8%,  14.3%,  
14.3%,  and 14.3%,  respectively,  in patients receiving 
palliative CCRT.  The 5-year rates of LC,  DMFS,  PFS,  
and OS were 53.4%,  22.3%,  24.4%,  and 37.3%,  
respectively,  in those receiving definitive CCRT and 
20.8%,  14.3%,  14.3%,  and 14.3%,  respectively,  in 
those receiving palliative CCRT.  In the univariate anal-
ysis of 55 patients,  palliative CCRT was associated with 
low rates of LC (p = 0.01),  DMFS (p = 0.03),  and PFS 
(p = 0.04),  and palliative CCRT was associated with a 
low rate of OS (p = 0.004).  In the multivariate analysis,  
palliative CCRT was associated with a low rate of OS 
(p = 0.049).
Discussion
In this study,  we examined the clinical outcomes of 
palliative CCRT with cisplatin/docetaxel in patients 
with stage III NSCLC.  Palliative CCRT was associated 
with poor outcomes in univariate and multivariate anal-
yses,  as demonstrated by four parameters (LC,  DMFS,  
PFS,  and OS),  compared with preoperative CCRT plus 
surgery or definitive.
The 2-year OS rate was low (22.2%) in patients in the 
palliative CCRT group.  As demonstrated by the rates of 
LC,  DMFS,  PFS,  and OS,  patients who underwent 
CCRT alone had significantly worse outcomes than 
those who underwent planned surgery.  Analysis of the 
Phase III trial of INT0139 showed improved OS in 
patients receiving preoperative CCRT plus lobectomy 
compared to patients receiving definitive CCRT.  
According to OS,  this study failed to show the superi-
ority of the preoperative CCRT group over the definitive 
CCRT group.  After randomization,  18.8% of patients 
could not undergo surgery and 7.7% could not undergo 
definitive CCRT.  This may be a reason why there was 
no difference in OS between the 2 groups.  Therefore,  it 
is highly advisable to avoid situations in which the ini-
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Fig. 1　 Kaplan－Meier curves 
for all patients who underwent 
palliative CCRT.  (A) Local con-
trol; (B) distant metastasis-free 
survival ; (C) progression-free 
survival; (D) overall survival.
CCRT,  concurrent chemoradio-
therapy.
tial treatment terminates with palliative CCRT without 
surgery.  Only 8.5% of patients who underwent preop-
erative CCRT were unsuitable for surgery; this was 
lower than the 18.8% in INT0139,  suggesting that the 
determination of the indication for treatment at our 
institution was appropriate.  However,  in our study,  7 
of 9 patients who underwent palliative CCRT did not 
undergo surgery because of distant metastases.  
Estimation of the group in which surgery is unlikely to 
be performed using volumetric positron emission 
tomography [14] and carefully determining the indica-
tions for preoperative CCRT may help to avoid termi-
nation of the initial treatment with palliative CCRT.  
Similar to the results of previous reports,  in our study 
the location of the lower lobe was a poor prognostic 
factor in the preoperative CCRT group [15].  A possible 
explanation for this association,  mentioned by Shien et 
al.,  could be that patients with tumors located in the 
lower lobes may have a wider spread of potential disease 
than an imaging-based diagnosis would indicate.
We reported the clinical outcome of palliative CCRT 
in patients who were considered for definitive CCRT but 
did not receive a definitive dose.  The ASTRO guidelines 
recommend the concurrent use of 2 platinum-contain-
ing chemotherapy agents in combination with low-frac-
tion,  moderate-dose palliative radiotherapy over either 
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Table 2　 Characteristics of patients who completed CCRT as preoperative treatment
Preoperative CCRT plus surgery (n=97) Palliative CCRT (n=9)
Age (years) Median (range) 61 (33-78) 64 (42-71)
Sex Male 75 8
Female 22 1








Clinical stage IIIA 65 7
IIIB 32 2
Histology Adenocarcinoma 48 2
Squamous cell carcinoma 34 6
Adenosquamous carcinoma 1 0
Undifferentiated carcinoma 1 0
Non-small cell carcinoma 13 1
Lobe Upper 69 5
Middle 6 0
Lower 17 4
Upper and lower 1 0
Middle and lower 4 0
Laterality Right 43 7
Left 54 2
Smoking history† Never 11 0
Former 16 4
Current 35 5
FEV1 (l)† Median (range) 2.55 (1.40-4.17) 2.29 (1.74-3.67)
ECOG-PS† 0 59 5
1 37 4
2 1 0
Radiation dose (Gy) Median (range) 46 (40-60) 46 (40-46)
CCRT,  concurrent chemoradiotherapy; ECOG-PS,  Eastern Cooperative Oncology Group performance status; FEV1,  forced expiratory 
volume in 1 sec.
†These factors have missing values.
treatment alone for stage III NSCLC in situations where 
resection or definitive dose administration is not possi-
ble [11].  Strøm et al.  conducted a phase III trial that 
compared palliative CCRT to chemotherapy alone [16].  
Treatment consisted of chemotherapy of carboplatin/
vinorelbine and radiotherapy of 42 Gy/15 fractions;  
2-year OS rates were 27.7% and 7.4% in the palliative 
CCRT and chemotherapy-alone groups,  respectively,  
showing a significant difference between the groups.  
Nawrocki et al.  also conducted a randomized phase II 
trial [17].  Treatment consisted of chemotherapy with 
cisplatin/vinorelbine and radiotherapy of 30 Gy/10 
fractions; 2-year OS rates were 24% and 6% in the pal-
liative CCRT and chemotherapy-alone groups,  respec-
tively,  indicating a significant difference.  Palliative 
CCRT is a meaningful treatment for the palliation of 
symptoms and the prolongation of survival.  To the best 
of our knowledge,  our report is the first to show that 
palliative CCRT with cisplatin/docetaxel resulted in a 
2-year OS rate of 14.3%,  slightly lower than those 
shown in previous studies.  Our study is retrospective 
and included a small number of cases,  which may have 
caused this difference.  Sundstrøm et al.  conducted a 
phase III study comparing three groups of radiotherapy 
regimens: the 3-year OS rate tended to be better in the 
42 Gy/15 and 50 Gy/25 fraction groups than in the 
17 Gy/2 fraction group,  according to the subgroup 
analyses of stage III patients with good performance 
status [18].  Further evidence on the total dose and 
fractions for palliative CCRT for prolonging prognosis 
is needed.  Patients in the definitive CCRT group who 
received palliative CCRT had a 2-year survival rate of 
14.3%,  higher than the 7.4% 2-year survival rate of the 
chemotherapy-alone group in the study conducted by 
Strøm et al.  [16].  Palliative CCRT with cisplatin/
docetaxel seems to be a more frequently recommended 
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Fig. 2　 Kaplan－Meier curves 
for preoperative CCRT plus sur-
gery (n=97) and palliative CCRT 
(n=9).  (A) Local control; (B) 
distant metastasis-free survival;  
(C) progression-free survival; (D) 
overall survival.  
CCRT,  concurrent chemoradio-
therapy.
treatment than chemotherapy alone,  although there are 
no data comparing the use of the two treatments at our 
institution.  In recent years,  molecular targeted drugs 
and immune checkpoint inhibitors have dramatically 
improved treatment outcomes of advanced NSCLC 
[19 , 20].  In case a patient with stage III NSCLC is not 
suitable for surgery and definitive CCRT,  the attending 
physician may have difficulty in determining the treat-
ment.  Hence,  our study could assist in the choice of the 
best treatment strategy.
Radiation can activate immune-related signals [21],  
and the addition of durvalumab after definitive CCRT 
can prolong OS in stage III lung cancer [22].  Improved 
prognosis may be expected if an immune checkpoint 
inhibitor is administered.  Levy et al.  treated patients 
with palliative radiotherapy and durvalumab [23];  
however,  further studies are needed to address this 
issue.
This study has some limitations.  It was a retrospec-
tive analysis and included a small number of patients.  
Because palliative CCRT was not performed to control 
symptoms,  symptomatic relief was not evaluated.  
Palliative CCRT was associated with worse outcomes 
than in ideal treatments; this result represents the 
tumor factor in addition to the treatment factor.  This 
study included a palliative CCRT patient group that 
completed CCRT as a preoperative treatment but did 
not undergo surgery,  and another palliative CCRT 
patient group that was considered for definitive CCRT 
but did not receive a definitive dose.  Since the palliative 
CCRT patient group that completed CCRT as a preop-
erative treatment was not operated upon,  mainly 
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Table 3　 Characteristics of patients who were considered for definitive CCRT
Definitive CCRT (n=48) Palliative CCRT (n=7)
Age (years) Median (range) 62 (35-84) 60 (49-72)
Sex Male 43 6
Female 5 1









Clinical stage IIIA 8 1
IIIB 40 6
Histology Adenocarcinoma 16 2
Squamous cell carcinoma 28 2
Adenosquamous carcinoma 0 1
Non-small cell carcinoma 4 2
Lobe† Upper 36 5
Lower 10 2
Laterality† Right 26 6
Left 20 1
Smoking history† Never 1 1
Former 21 1
Current 25 4
FEV1 (l)† Median (range) 2.34 (0.48-4.11) 2.28 (2.17-2.49)
ECOG-PS† 0 18 1
1 29 6
Radiation dose (Gy) Median (range) 60 (54-60) 44 (40-46)
CCRT,  concurrent chemoradiotherapy; ECOG-PS,  Eastern Cooperative Oncology Group performance status; FEV1,  forced expiratory 
volume in 1 sec.
†These factors have missing values.
because of the appearance of distant metastases,  it is not 
surprising that the DMFS and PFS of this group were 
lower than those of patient group that underwent sur-
gery.  This retrospective study has these two biases and 
thus its results should be interpreted with caution.
In conclusion,  the clinical outcomes of palliative 
CCRT were significantly inferior to those of the ideal 
treatments,  although there were some long-term survi-
vors.  Therefore,  careful determination of the appropri-
ate treatment indication and further studies are war-
ranted.
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